ArticleBMC infectious diseases2026
Bioactive adrenomedullin as a point-of-care biomarker in emergency department patients with suspected severe infections: an exploratory analysis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly identification and treatment of patients with severe infections or sepsis remains challenging, and suitable biomarkers are lacking. This prospective exploratory pilot study aimed to evaluate the potential of point-of-care bioactive adrenomedullin (POC bio-ADM) in predicting bacteremia in patients presenting to the emergency department (ED) with suspected severe infections. Secondary objectives included its association with any infection, in-hospital mortality, intensive care unit (ICU) admission, and ICU length of stay.
methodsIn this prospective exploratory pilot cohort study, adult patients presenting to the ED of a German university hospital between December 2022 and September 2023 were enrolled. POC bio-ADM levels were analyzed using univariate and multivariable binary logistic regression and compared to established sepsis biomarkers (PCT, CRP, lactate).
results47 patients were included in the final analysis. POC bio-ADM was positive (> 45 pg/ml) in 38.3% (95% CI: 25.8–52.6%). Bacteremia was found in 34.0% (95% CI: 22.2–48.3%), and 78.7% (95% CI: 65.1–88.8%) had an infection. Positive POC bio-ADM was associated with significantly higher rates of bacteremia (55.6% vs. 20.7%). In the multivariable analysis, a positive POC bio-ADM was associated with an odds ratio (OR) of 5.318 (95% CI: 1.217–23.243) for bacteremia. Attributable in-hospital mortality was higher in patients with elevated POC bio-ADM (44.4% vs. 3.6%; OR: 21.6, 95% CI: 2.4-195.3).
conclusionThis small, single-centre pilot exploratory study suggests that POC bio-ADM may help identify ED patients with suspected severe infection at increased risk of bacteremia and in-hospital mortality; these findings are hypothesis-generating and require confirmation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.